Immunotherapy drug successfully reduced antibodies to allow kidney transplantation The newly approved drug vastly reduced the amount of antibodies that would usually lead to organ rejection in a patient who had no chance of receiving a matched transplant. Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/immunotherapy-drug-successfully-reduced-antibodies-to-allow-kidney-transplantation-17424 A 37-year-old man who once had no hope of receiving a matched donor kidney is now living dialysis-free with a new kidney that has excellent function. After spending 12 years on an organ waiting list, the joyful outcome came thanks to a new drug recently approved from Johnson & Johnson to treat multiple myeloma, called teclistamab. The drug is a bispecific T cell engager antibody that works by activating T cells and binding to B-cell maturation antigen (BCMA) on the target cells to tag them for destruction.